RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

BACKGROUND: RORγt is a transcription factor that enables elaboration of Th17-associated cytokines (including IL-17 and IL-22) and is proposed as a pharmacological target for severe asthma. METHODS: IL-17 immunohistochemistry was performed in severe asthma bronchial biopsies (specificity confirmed wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamb, David, De Sousa, Dorothy, Quast, Karsten, Fundel-Clemens, Katrin, Erjefält, Jonas S., Sandén, Caroline, Hoffmann, Hans Jürgen, Kästle, Marc, Schmid, Ramona, Menden, Kevin, Delic, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141258/
https://www.ncbi.nlm.nih.gov/pubmed/34022896
http://dx.doi.org/10.1186/s12931-021-01743-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141258/
https://www.ncbi.nlm.nih.gov/pubmed/34022896
http://dx.doi.org/10.1186/s12931-021-01743-7

Ejemplares similares